Myocardial Dystrophy In Chronic Obstructive Pulmonary Disease: Mechanisms Of Development, Early Markers, And Treatment Approaches
DOI:
https://doi.org/10.62480/tjms.2026.vol56.pp8-10Keywords:
chronic obstructive pulmonary disease, myocardial dystrophy, cor pulmonaleAbstract
This article examines the relationship between chronic obstructive pulmonary disease (COPD) and myocardial dystrophy, focusing on pathophysiological mechanisms, diagnostic approaches, and therapeutic strategies. A total of 120 COPD patients were evaluated for myocardial dysfunction using echocardiography, cardiac biomarkers (NT-proBNP, troponin I, CK-MB), and inflammatory markers (IL6, TNF-α, CRP). The results demonstrated that myocardial dystrophy is present in 68.3% of COPD patients, with severity correlating with disease stage. Hypoxia-driven oxidative stress and systemic inflammation were identified as the primary mechanisms. Combined bronchodilator therapy supplemented with cardioprotective agents (trimetazidine 35 mg twice daily) significantly improved both pulmonary and cardiac functional parameters.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
User Rights
Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).
Rights of Authors
Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.
